Revive Therapeutics Ltd (RVVTF)

[Ecomike]

This weeks old news alone is a massive clue, Massive!!!

"Revive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation • InvestorsHub NewsWire • 02/16/2022 01:03:51 PM"

That does not happen for something the FDA is going deny an EUA approval for....

IMO, there is a connection there. And that designation is worth about 3 Million dollars of cost savings, and gives $RVVTF rights to it, on safely used for 30 years drug, used for RA....